Physician profile
John Scrivano
NPI 1235224395
$9,020.97
in general payments reported to CMS, 2019-2025
39 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,876 · 2022: $2,418 · 2023: $1,766 · 2024: $1,212 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,727.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,138.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,668.37 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,132.67 | 2021-2025 | |
| Lilly USA, LLC | $850.13 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $656.69 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $412.28 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.58 | 2021-2025 | Tradjenta, Jardiance |
| Dexcom, INC. | $313.80 | 2022-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $155.22 | 2022-2025 | |
| Abbott Laboratories | $153.37 | 2022-2025 | Freestyle Libre 3, Octrode |
| Esperion Therapeutics, INC. | $95.49 | 2021-2023 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $87.10 | 2025 | Zoryve |
| Amgen INC. | $86.14 | 2021-2023 | Repatha |
| Merck Sharp & Dohme LLC | $80.22 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $70.40 | 2021-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Scrivano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.